069620.KS
Daewoong Pharmaceutical Co., Ltd
KSEKRWEQUITY
Healthcare
DELAYED
Last price
119,500.00
▼ 1,400.00 (1.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
118,900.00
Prev close
120,900.00
Day high
120,500.00
Day low
116,200.00
Volume
15.75K
Market cap
$1.37T
P/E (TTM)
—
52W range
105,000.00 – 199,400.00
Day trading desk
Gap from prior close
-1.65%
Prior close 120,900.00
VWAP
118,363.83
+0.96% from price
Relative volume
0.41×
Quiet session
Session range
3.70%
116,200.00 – 120,500.00
Position in range
77%
Near session high
ATR (14D)
5,364.29
4.49% of price
Prior day high
122,500.00
PDH
Prior day low
119,600.00
PDL
Bid / ask spread
—
Quote not published
Session volume
16.11K
Avg 39.56K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.08%
-1.7%
1M
-0.17%
-3.9%
3M
-8.57%
-11.7%
6M
-31.08%
-42.1%
YTD
-30.64%
-42.9%
1Y
-12.39%
-32.4%
3Y
+28.77%
-45.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 069620.KS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.07M
Total on file
Fundamentals
Market cap$1.37T
Enterprise value$2.27T
Revenue (TTM)$1.64T
Gross profit$854.64B
EBITDA$256.82B
Net income$195.47B
EPS (TTM)—
Free cash flow$-174.76B
Total cash$158.42B
Total debt$925.02B
Book value / share—
Shares outstanding11.51M
Float5.38M
Short % of float—
Dividend yield0.50%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue1.39
EV / EBITDA8.84
Gross margin52.26%
Operating margin15.18%
Profit margin11.95%
Return on equity16.63%
Return on assets5.09%
Debt / equity77.64
Current ratio0.89
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.57T | $1.42T | $1.38T | $1.28T | +10.4% |
| Operating revenue | $1.57T | $1.42T | $1.38T | $1.28T | +10.4% |
| Cost of revenue | $748.36B | $688.52B | $687.16B | $641.13B | +8.7% |
| Gross profit | $822.53B | $734.17B | $688.17B | $638.96B | +12.0% |
| Research & development | $180.31B | $171.29B | $171.57B | $163.60B | +5.3% |
| Selling, general & admin | $294.89B | $269.33B | $257.00B | $245.42B | +9.5% |
| Total operating expense | $625.75B | $586.23B | $565.57B | $543.16B | +6.7% |
| Operating income | $196.78B | $147.94B | $122.59B | $95.80B | +33.0% |
| Net interest income | -$9.88B | -$1.89B | -$10.50B | $3.67B | -421.7% |
| Pre-tax income | $191.83B | $56.55B | $122.00B | $38.33B | +239.2% |
| Tax provision | -$1.08B | $33.20B | $2.00B | -$833.51M | -103.2% |
| Net income | $195.86B | $24.73B | $121.74B | $42.24B | +691.8% |
| Net income to common | $195.86B | $24.73B | $121.74B | $42.24B | +691.8% |
| Basic EPS | 17,022.00 | 2,150.00 | 10,656.00 | 3,816.00 | +691.7% |
| Diluted EPS | 17,022.00 | 2,150.00 | 10,656.00 | 3,816.00 | +691.7% |
| EBIT | $204.31B | $63.54B | $135.60B | $46.74B | +221.6% |
| EBITDA | $255.38B | $112.52B | $179.40B | $86.43B | +127.0% |
| Basic shares | 11.51M | 11.50M | 11.42M | 11.07M | +0.0% |
| Diluted shares | 11.51M | 11.50M | 11.42M | 11.07M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $168.94B | $102.95B | $111.51B | $102.95B | +64.1% |
| Cash & short-term investments | $172.80B | $116.35B | $137.68B | $140.65B | +48.5% |
| Accounts receivable | $166.72B | $160.74B | $137.51B | $142.16B | +3.7% |
| Inventory | $310.88B | $256.35B | $241.55B | $208.74B | +21.3% |
| Total current assets | $732.36B | $612.79B | $574.82B | $548.97B | +19.5% |
| Property, plant & equipment | $842.34B | $675.67B | $521.92B | $440.89B | +24.7% |
| Goodwill & intangibles | $367.52B | $346.71B | $297.48B | $266.01B | +6.0% |
| Total assets | $2.36T | $1.98T | $1.77T | $1.56T | +19.5% |
| Total current liabilities | $588.82B | $629.42B | $695.53B | $472.83B | -6.4% |
| Current debt | $276.78B | $321.50B | $372.37B | $233.67B | -13.9% |
| Long-term debt | $550.56B | $324.48B | $65.00B | $204.84B | +69.7% |
| Total debt | $829.39B | $649.25B | $441.27B | $446.71B | +27.7% |
| Total liabilities | $1.23T | $1.05T | $858.03B | $822.12B | +17.0% |
| Retained earnings | $833.60B | $635.67B | $618.86B | $504.29B | +31.1% |
| Shareholder equity | $1.01T | $794.64B | $767.30B | $608.02B | +26.6% |
| Working capital | $143.53B | -$16.62B | -$120.71B | $76.14B | +963.5% |
| Net tangible assets | $638.57B | $447.93B | $469.82B | $342.01B | +42.6% |
| Shares issued | 11.51M | 11.59M | 11.59M | 11.59M | -0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $192.91B | $23.35B | $120.00B | $39.16B | +726.3% |
| Depreciation & amortisation | $51.07B | $48.98B | $43.80B | $39.69B | +4.3% |
| Stock-based compensation | $475.96M | $545.31M | $1.62B | $1.84B | -12.7% |
| Change in working capital | -$74.47B | -$82.79B | -$20.72B | $31.58B | +10.1% |
| Operating cash flow | $149.21B | $51.49B | $136.01B | $118.21B | +189.8% |
| Capital expenditure | -$241.37B | -$229.00B | -$156.17B | -$113.31B | -5.4% |
| Investing cash flow | -$247.03B | -$265.45B | -$165.62B | -$106.87B | +6.9% |
| Dividends paid | -$8.08B | -$7.74B | -$7.28B | -$8.07B | -4.3% |
| Financing cash flow | $164.35B | $200.62B | $39.22B | $15.52B | -18.1% |
| Free cash flow | -$92.16B | -$177.51B | -$20.16B | $4.91B | +48.1% |
| End cash position | $168.94B | $102.95B | $111.51B | $102.95B | +64.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $377.80B | $397.12B | $411.83B | $405.45B | $356.49B | -4.9% |
| Operating revenue | $377.80B | $397.12B | $411.83B | $405.45B | $356.49B | -4.9% |
| Cost of revenue | $196.61B | $186.75B | $197.83B | $190.37B | $173.41B | +5.3% |
| Gross profit | $181.19B | $210.37B | $214.00B | $215.08B | $183.08B | -13.9% |
| Research & development | $44.98B | $139.98B | $8.31B | $44.89B | $42.24B | -67.9% |
| Selling, general & admin | $73.28B | $12.07B | $103.80B | $75.04B | $63.52B | +507.0% |
| Total operating expense | $158.98B | $167.03B | $157.11B | $157.23B | $144.38B | -4.8% |
| Operating income | $22.21B | $43.34B | $56.89B | $215.08B | $38.70B | -48.8% |
| Net interest income | -$2.13B | -$2.41B | $1.54B | -$9.75B | -$2.52B | +11.6% |
| Pre-tax income | $33.97B | $68.97B | $54.73B | $43.40B | $24.73B | -50.7% |
| Tax provision | $8.46B | -$16.73B | $7.42B | $3.28B | $4.95B | +150.5% |
| Net income | $25.90B | $89.84B | $46.37B | $37.76B | $21.89B | -71.2% |
| Net income to common | $25.90B | $89.84B | $46.37B | $37.76B | $21.89B | -71.2% |
| Basic EPS | 2,251.00 | — | 4,030.00 | 3,281.00 | 1,903.00 | — |
| Diluted EPS | 2,251.00 | — | 4,030.00 | 3,281.00 | 1,903.00 | — |
| EBIT | $36.72B | $72.50B | $56.89B | $57.86B | $27.67B | -49.4% |
| EBITDA | $52.89B | $86.47B | $69.45B | $70.15B | $39.91B | -38.8% |
| Basic shares | 11.51M | — | 11.51M | 11.51M | 11.51M | — |
| Diluted shares | 11.51M | — | 11.51M | 11.51M | 11.51M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.66B | $168.94B | $204.26B | $159.58B | $97.78B | -3.1% |
| Cash & short-term investments | $168.03B | $172.80B | $208.62B | $164.23B | $102.86B | -2.8% |
| Accounts receivable | $170.58B | $166.72B | $172.08B | $168.80B | $165.90B | +2.3% |
| Inventory | $314.98B | $310.88B | $312.36B | $298.73B | $274.39B | +1.3% |
| Total current assets | $737.90B | $732.36B | $789.51B | $707.47B | $621.78B | +0.8% |
| Property, plant & equipment | $903.88B | $842.34B | $762.92B | $699.19B | $683.64B | +7.3% |
| Goodwill & intangibles | $384.50B | $367.52B | $371.20B | $365.25B | $354.04B | +4.6% |
| Total assets | $2.45T | $2.36T | $2.26T | $2.11T | $1.99T | +3.7% |
| Total current liabilities | $656.76B | $588.82B | $683.90B | $636.07B | $590.43B | +11.5% |
| Current debt | $347.23B | $276.78B | $309.32B | $310.33B | $289.07B | +25.5% |
| Long-term debt | $550.82B | $550.56B | $481.49B | $420.50B | $373.85B | +0.0% |
| Total debt | $900.43B | $829.39B | $793.01B | $733.58B | $666.09B | +8.6% |
| Total liabilities | $1.30T | $1.23T | $1.26T | $1.15T | $1.06T | +5.5% |
| Retained earnings | $852.46B | $833.60B | $734.74B | $688.37B | $650.62B | +2.3% |
| Shareholder equity | $1.03T | $1.01T | $879.85B | $831.64B | $804.24B | +2.0% |
| Working capital | $81.13B | $143.53B | $105.61B | $71.39B | $31.35B | -43.5% |
| Net tangible assets | $641.50B | $638.57B | $508.65B | $466.39B | $450.20B | +0.5% |
| Shares issued | 11.59M | 11.51M | 11.59M | 11.59M | 11.59M | +0.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $25.51B | $85.70B | $47.31B | $40.12B | $19.78B | — | -70.2% |
| Depreciation & amortisation | $16.17B | $13.97B | $12.56B | $12.30B | $12.25B | — | +15.7% |
| Stock-based compensation | -$700.31M | $145.38M | $112.54M | $105.21M | $112.83M | — | -581.7% |
| Change in working capital | -$23.06B | -$6.15B | -$9.15B | -$19.83B | -$39.33B | — | -274.8% |
| Operating cash flow | $17.21B | $40.35B | $57.53B | $48.24B | $3.08B | — | -57.3% |
| Capital expenditure | -$94.81B | -$101.43B | -$72.21B | -$37.43B | -$30.29B | — | +6.5% |
| Investing cash flow | -$90.98B | -$107.41B | -$73.82B | -$43.85B | -$21.95B | — | +15.3% |
| Dividends paid | -$977.63M | -$9.00M | -$1.16B | — | — | -$7.78M | -10,762.5% |
| Financing cash flow | $65.76B | $32.09B | $57.48B | $60.96B | $13.82B | — | +104.9% |
| Free cash flow | -$77.60B | -$61.08B | -$14.68B | $10.81B | -$27.21B | — | -27.0% |
| End cash position | $163.66B | $168.94B | $204.26B | $159.58B | $97.78B | — | -3.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $479.25B | +35.0% |
| Next quarter | — | — | $386.60B | +8.6% |
| Current year | 15,085.53 | 3 | $1.69T | +7.7% |
| Next year | 17,556.75 | 4 | $1.77T | +4.8% |
Analyst targets & ownership
Mean target$204,444.44
High target$220,000.00
Low target$180,000.00
Implied upside71.08%
Analyst count9
ConsensusNONE
Strong buy / Buy5 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders61.48%
Held by institutions19.56%
Institutions holding60
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
123,850.00
-3.51% from price
SMA 20
123,585.00
-3.31% from price
SMA 50
122,624.00
-2.55% from price
SMA 100
133,224.00
-10.30% from price
SMA 200
150,885.50
-20.80% from price
EMA 12
122,334.09
-2.32% from price
EMA 26
123,296.28
-3.08% from price
EMA 50
125,565.06
-4.83% from price
RSI (14)
44.9
Neutral
MACD (12,26,9)
-962.19
Hist -627.14
ATR (14)
5,364.29
4.49% of price
Realised vol 30D
55.0%
Annualised
Bollinger upper
133,010.34
20, 2σ
Bollinger lower
114,159.66
20, 2σ
50 / 200 cross
Death
122,624.00 vs 150,885.50
Trend bias
Below 200
-20.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.01
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
55.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-44.7%
Peak to trough
Max drawdown 5Y
-52.3%
Peak to trough
ATR 14
5,364.29
4.49% of price
Beta (reported)
—
5Y monthly, from filing
Dividends & splits
Forward rate$600.00 / yr
Forward yield0.50%
5-year avg yield0.45%
Payout ratio3.53%
Ex-dividend dateDec 29, 2025
Next pay date—
Last split1.03:1
Split dateDec 27, 2012
Headlines
What Happens When Social Security Takes Your Benefits Because You Work Too Much?
Motley Fool · 9m ago
Carney warned about economic coercion. Now Trump is testing the Canadian prime minister
Associated Press · 17m ago
Alibaba Launches Record $10 Billion Share Sale to Enter the AI Race
BeInCrypto · 20m ago
Pershing Square (PS) Following Earnings Loss And New Venture Launch Faces A Valuation Test
Simply Wall St. · 21m ago
Tenet Healthcare (THC) Stock May Be 49% Undervalued After Raised Outlook
Simply Wall St. · 21m ago
Morgan Housel warns of a looming career threat for your child
TheStreet · 22m ago
History Says You Should Know These 3 Things Before Buying the Vanguard S&P 500 ETF (VOO)
Motley Fool · 24m ago
He Camped One Weekend on Riverfront Land Inside His IRA. Medicare Charged Him for It Two Years Later.
24/7 Wall St. · 26m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.